Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EVAX Stock Forecast 2026-2027
$4.45
Current Price
$37.11M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to EVAX Price Targets
+259.6%
To High Target of $16.00
+124.7%
To Median Target of $10.00
+102.2%
To Low Target of $9.00
EVAX Price Momentum
+7.5%
1 Week Change
+13.8%
1 Month Change
+239.7%
1 Year Change
-6.7%
Year-to-Date Change
-63.4%
From 52W High of $12.15
+256.0%
From 52W Low of $1.25
📊 TOP ANALYST CALLS
Did EVAX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Evaxion is one of their latest high-conviction picks.
Latest EVAX Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, EVAX has a bullish consensus with a median price target of $10.00 (ranging from $9.00 to $16.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $4.45, the median forecast implies a 124.7% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Swayampakula Ramakanth at HC Wainwright & Co., projecting a 259.6% upside. Conversely, the most conservative target is provided by Thomas Flaten at Lake Street, suggesting a 102.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EVAX Analyst Ratings
4
Buy
0
Hold
0
Sell
EVAX Price Target Range
Low
$9.00
Average
$10.00
High
$16.00
Current: $4.45
Latest EVAX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EVAX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 10, 2026 | Jones Trading | Buy | Initiates | $10.00 | |
| Mar 9, 2026 | Lake Street | Thomas Flaten | Buy | Maintains | $9.00 |
| Mar 9, 2026 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $16.00 |
| Oct 30, 2025 | Edward Jones | Soumit Roy | Buy | Initiates | $10.00 |
| Oct 20, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $16.00 |
| Oct 20, 2025 | Lake Street | Thomas Flaten | Buy | Maintains | $11.00 |
| Sep 25, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $16.00 |
| Apr 2, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Feb 20, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Feb 4, 2025 | Lake Street | Thomas Flaten | Buy | Maintains | $6.00 |
| Feb 3, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Nov 1, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Sep 26, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Sep 20, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Aug 16, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Jun 4, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Apr 3, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Apr 2, 2024 | Ladenburg Thalmann | Ahu Demir | Buy | Upgrade | $8.00 |
| Mar 20, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
Evaxion Biotech A/S (EVAX) Competitors
The following stocks are similar to Evaxion based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
EVAX
Evaxion Biotech
mkt cap
37.11M
Evaxion Biotech A/S (EVAX) Financial Data
Valuation Metrics
Market Cap
$37.11M
Enterprise Value
$1.71B
P/E Ratio
N/A
PEG Ratio
-6.9x
Price/Sales
4.6x
Growth & Margins
Revenue Growth (YoY)
-100.0%
Gross Margin
N/A
Operating Margin
-122.7%
Net Margin
-102.4%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+1.3%
Current Ratio
5.8x
Debt/Equity
44.0x
ROE
-100.2%
ROA
-28.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Evaxion Biotech A/S (EVAX) Business Model
About Evaxion Biotech A/S
What They Do
Develops AI-driven immunotherapies for cancer and infections.
Business Model
The company utilizes artificial intelligence to enhance the drug discovery process, focusing on predicting immune responses and identifying target candidates for therapeutic interventions. By operating within the pharmaceutical and biotechnology sectors, Evaxion Biotech A/S generates revenue through the development of innovative therapies that aim to improve treatment effectiveness.
Additional Information
Based in Denmark, Evaxion is at the forefront of integrating AI with biotechnology, positioning itself as a key player in the market for precision medicine. Its approach reflects a growing trend in the industry towards leveraging advanced technologies to create personalized therapies for patients.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
46
CEO
Dr. Birgitte Rono Ph.D.
Country
Denmark
IPO Year
2020
Website
evaxion.aiEvaxion Biotech A/S (EVAX) Latest News & Analysis
Latest News
Quick Summary
Evaxion A/S (NASDAQ: EVAX) announced new data showing its AI-Immunology™ platform effectively identifies key vaccine targets. The findings will be presented at the AACR Annual Meeting on April 22, 2026.
Why It Matters
Evaxion's new data on AI-Immunology™ highlights its potential to enhance vaccine development, possibly leading to competitive advantages and increased investor confidence in its growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Evaxion concludes Annual General Meeting
3 days ago
Quick Summary
Evaxion A/S (NASDAQ: EVAX) held its Annual General Meeting in Copenhagen, focusing on its AI-Immunology™ platform for developing novel vaccines.
Why It Matters
Evaxion's AGM highlights its focus on AI-driven vaccine development, signaling potential for innovation and future growth, impacting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress
21 days ago
Quick Summary
Evaxion A/S (NASDAQ: EVAX) is set to present novel vaccine designs for polio, developed with the Gates Foundation, at the World Vaccine Congress in Washington D.C. from March 31 to April 2, 2026.
Why It Matters
Evaxion's collaboration with the Gates Foundation and innovative vaccine concepts could enhance its market position and drive future revenue, impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Evaxion A/S (NASDAQ: EVAX) will hold its Annual General Meeting on April 16, 2026, at 14:00 CET, focusing on its AI-Immunology™ vaccine development.
Why It Matters
Evaxion's AGM may reveal strategic updates and financial performance, influencing investor sentiment and stock performance ahead of its vaccine developments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Evaxion A/S (EVAX) held its Q4 2025 earnings call, discussing financial performance and strategic updates. Specific earnings details were shared during the call.
Why It Matters
The Q4 2025 earnings call provides insights into Evaxion A/S's financial performance and strategic direction, influencing investor expectations and potential stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Evaxion A/S (NASDAQ: EVAX) will delay the filing of its 2025 annual report due to technical issues with external vendors, initially set for publication before Nasdaq CM opening.
Why It Matters
Evaxion's delay in filing its annual report raises concerns about operational efficiency and transparency, potentially impacting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About EVAX Stock
What is Evaxion Biotech A/S's (EVAX) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Evaxion Biotech A/S (EVAX) has a median price target of $10.00. The highest price target is $16.00 and the lowest is $9.00.
Is EVAX stock a good investment in 2026?
According to current analyst ratings, EVAX has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.45. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EVAX stock?
Wall Street analysts predict EVAX stock could reach $10.00 in the next 12 months. This represents a 124.7% increase from the current price of $4.45. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Evaxion Biotech A/S's business model?
The company utilizes artificial intelligence to enhance the drug discovery process, focusing on predicting immune responses and identifying target candidates for therapeutic interventions. By operating within the pharmaceutical and biotechnology sectors, Evaxion Biotech A/S generates revenue through the development of innovative therapies that aim to improve treatment effectiveness.
What is the highest forecasted price for EVAX Evaxion Biotech A/S?
The highest price target for EVAX is $16.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 259.6% increase from the current price of $4.45.
What is the lowest forecasted price for EVAX Evaxion Biotech A/S?
The lowest price target for EVAX is $9.00 from Thomas Flaten at Lake Street, which represents a 102.2% increase from the current price of $4.45.
What is the overall EVAX consensus from analysts for Evaxion Biotech A/S?
The overall analyst consensus for EVAX is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are EVAX stock price projections?
Stock price projections, including those for Evaxion Biotech A/S, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 2:49 AM UTC